Hans-Peter Hartung Selected Research

Interferon-beta

1/2019	Detection and kinetics of persistent neutralizing anti-interferon-beta antibodies in patients with multiple sclerosis. Results from the ABIRISK prospective cohort study.
1/2017	Clinical practice of analysis of anti-drug antibodies against interferon beta and natalizumab in multiple sclerosis patients in Europe: A descriptive study of test results.
8/2013	Interleukin 17F level and interferon β response in patients with multiple sclerosis.
11/2012	Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial.
6/2012	Variability in detection and quantification of interferon β-1b-induced neutralizing antibodies.
5/2011	Neutralizing antibodies in interferon beta treated patients with multiple sclerosis: knowing what to do now : Commentary to: 10.1007/s00415-010-5844-5 "One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients" by S. Malucchi et al.
4/2011	Influence of the HLA-DRB1 genotype on antibody development to interferon beta in multiple sclerosis.
9/2010	Inhibition of endogenous interferon beta by neutralizing antibodies against recombinant interferon beta.
7/2010	Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis.
10/2009	Enhancement of chemokine expression by interferon beta therapy in patients with multiple sclerosis.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Hans-Peter Hartung Research Topics

Disease

212	Multiple Sclerosis 10/2022 - 12/2002
43	Relapsing-Remitting Multiple Sclerosis 01/2021 - 05/2003
39	Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) 01/2022 - 04/2002
28	Demyelinating Diseases (Demyelinating Disease) 01/2022 - 12/2002
25	Polyneuropathies (Polyneuropathy) 01/2022 - 06/2005
24	Infections 01/2022 - 03/2003
22	Experimental Autoimmune Encephalomyelitis (Encephalomyelitis, Autoimmune Experimental) 01/2022 - 06/2004
18	Chronic Progressive Multiple Sclerosis 12/2020 - 12/2002
17	Neuromyelitis Optica (Devic's Disease) 01/2022 - 02/2012
17	Progressive Multifocal Leukoencephalopathy 01/2021 - 02/2007
14	Inflammation (Inflammations) 10/2022 - 04/2002
14	Guillain-Barre Syndrome 01/2020 - 04/2002
12	Stroke (Strokes) 09/2020 - 07/2004
11	Disease Progression 07/2022 - 06/2004
9	Autoimmune Diseases (Autoimmune Disease) 10/2020 - 03/2006
9	Ischemic Stroke 09/2020 - 07/2004
9	Neoplasms (Cancer) 07/2020 - 03/2006
8	Optic Neuritis (Retrobulbar Neuritis) 01/2022 - 01/2012
7	Nervous System Diseases (Neurological Disorders) 01/2021 - 07/2006
6	Atrophy 03/2022 - 07/2013
6	Myasthenia Gravis 01/2022 - 07/2006
6	COVID-19 01/2022 - 06/2020
5	Headache (Headaches) 04/2020 - 09/2010
5	Experimental Autoimmune Neuritis 01/2018 - 02/2004
4	Pain (Aches) 01/2022 - 10/2004
4	Autoimmune Diseases of the Nervous System 11/2021 - 03/2010
4	Rheumatoid Arthritis 10/2020 - 01/2009
4	Opportunistic Infections (Opportunistic Infection) 04/2020 - 02/2007
4	Infarction (Infarctions) 01/2020 - 06/2012
4	Ganglion Cysts (Ganglion) 11/2019 - 01/2012
3	Myositis (Idiopathic Inflammatory Myopathies) 11/2021 - 09/2006
3	Encephalitis (Encephalitis, Rasmussen) 11/2021 - 10/2007
3	Lymphopenia (Lymphocytopenia) 04/2020 - 12/2014
3	Atrioventricular Block 11/2019 - 02/2010
3	Human Influenza (Influenza) 01/2019 - 09/2010
3	Neuroinflammatory Diseases 01/2019 - 01/2016
3	Macular Edema 10/2017 - 02/2010
3	Leukocytosis (Pleocytosis) 11/2007 - 04/2003

Drug/Important Bio-Agent (IBA)

33	Natalizumab (Tysabri)FDA Link 01/2021 - 04/2005
27	Interferon-betaIBA 01/2019 - 06/2003
24	Intravenous Immunoglobulins (IVIG)FDA Link 01/2022 - 02/2008
22	Fingolimod Hydrochloride (FTY720)FDA Link 05/2022 - 02/2010
22	Pharmaceutical PreparationsIBA 01/2019 - 12/2002
18	Monoclonal AntibodiesIBA 10/2022 - 04/2005
17	AntibodiesIBA 10/2022 - 12/2002
17	Retinaldehyde (Retinal)IBA 01/2022 - 01/2012
17	InterferonsIBA 02/2021 - 05/2003
17	Interferon beta-1a FDA Link 11/2019 - 09/2005
15	Proteins (Proteins, Gene)FDA Link 11/2021 - 03/2003
14	Immunoglobulin G (IgG)IBA 01/2022 - 07/2005
14	Immunoglobulins (Immunoglobulin)IBA 01/2022 - 11/2007
13	Alemtuzumab (Campath)FDA Link 12/2021 - 01/2009
13	Interferon beta-1b (Betaseron)FDA Link 01/2020 - 08/2007
11	Mitoxantrone (Novantrone)FDA LinkGeneric 01/2012 - 12/2002
10	ocrelizumabIBA 01/2022 - 10/2016
10	HizentraIBA 01/2022 - 01/2016
10	Glatiramer Acetate (Copaxone)FDA Link 01/2021 - 06/2003
10	CytokinesIBA 01/2016 - 12/2002
9	Cladribine FDA LinkGeneric 11/2021 - 02/2010
9	Biomarkers (Surrogate Marker)IBA 11/2020 - 07/2004
8	Myelin-Oligodendrocyte GlycoproteinIBA 01/2022 - 12/2006
8	Rituximab (Mabthera)FDA Link 01/2022 - 10/2005
8	VaccinesIBA 12/2021 - 09/2010
8	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 01/2017 - 05/2004
7	Sphingosine-1-Phosphate ReceptorsIBA 01/2022 - 10/2012
7	GadoliniumIBA 04/2021 - 04/2014
7	AntigensIBA 01/2021 - 02/2004
7	Biological ProductsIBA 10/2020 - 06/2004
7	Immunosuppressive Agents (Immunosuppressants)IBA 10/2020 - 06/2004
6	AutoantibodiesIBA 01/2022 - 12/2006
6	Neutralizing AntibodiesIBA 06/2012 - 06/2004
5	ozanimodIBA 10/2022 - 01/2019
5	tocilizumab (atlizumab)FDA Link 01/2022 - 03/2013
5	4-Aminopyridine (4 Aminopyridine)FDA Link 01/2021 - 11/2012
5	CaprylatesIBA 02/2012 - 02/2008
4	temelimabIBA 03/2022 - 12/2012
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2022 - 01/2018
4	inebilizumabIBA 01/2022 - 10/2019
4	TabletsIBA 04/2021 - 01/2013
4	Aquaporins (Water Channels)IBA 01/2016 - 02/2012
3	Interleukin-6 Receptors (Interleukin 6 Receptor)IBA 01/2022 - 03/2013
3	RNA (Ribonucleic Acid)IBA 01/2022 - 06/2006
3	siponimodIBA 01/2022 - 08/2013
3	N-Methyl-D-Aspartate Receptors (NMDA Receptors)IBA 11/2021 - 10/2009
3	Anti-Bacterial Agents (Antibiotics)IBA 10/2020 - 11/2012
3	Vitamin D FDA LinkGeneric 01/2020 - 03/2014
3	Oligoclonal BandsIBA 05/2019 - 12/2014
3	Peptides (Polypeptides)IBA 01/2019 - 11/2005
3	SteroidsIBA 10/2018 - 06/2011
3	Simvastatin (Zocor)FDA LinkGeneric 01/2016 - 01/2005
3	IntegrinsIBA 01/2015 - 04/2005
3	Immunomodulating AgentsIBA 01/2013 - 06/2004
3	ChemokinesIBA 10/2009 - 04/2002
2	Complement System Proteins (Complement)IBA 01/2022 - 11/2016

Therapy/Procedure

107	Therapeutics 10/2022 - 12/2002
16	Immunotherapy 01/2022 - 07/2005
9	Immunomodulation 01/2022 - 03/2003
6	Plasma Exchange 11/2018 - 07/2006
3	Transplantation 09/2014 - 09/2006
3	Treatment Delay 07/2013 - 11/2009